Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Inclusion Criteria: * Female patients, age at diagnosis 18 - 75 years * Histological confirmed unilateral primary invasive carcinoma of the breast * Adequate surgical treatment with complete resection of the tumor (R0) and resection of \> or = 10 axillary nodes or SLN in clinically N0 patients * Node positive disease or node negative disease with at least one other risk factor (tumor size \> or = 2 cm, grade \> or = II) * No evidence for distant metastasis (M0) after conventional staging * Performance Status ECOG \< or = 1 * The patient must be accessible for treatment and follow-up * LVEF\> 50% * Negative pregnancy test (urine or serum) within 7 days prior to randomization in premenopausal patients * Leucocytes \> or = 4 x 10\^9/L * platelets \> or = 100 x 10\^9/L * haemoglobin \> or = 9 g/dL * total bilirubin \< or = 1.5 UNL * ASAT (SGOT) and ALAT (SGPT) \< or = 2.5 UNL * creatinine \< 175 mmol/L (2 mg/dL) Exclusion Criteria: 1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy）; 2. Has bilateral breast cancer; 3. Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ. 4. Has metastic (Stage 4) breast cancer; 5. Has any \>T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer); 6. Is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives; 7. Patients participating in other clinical trials at the same time; 8. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; 9. Has known allergy to taxane and excipients; 10. Has severe or uncontrolled infection.